TSH and prolactin stimulation by the decarboxylase inhibitor benserazide in primary hypothyroidism.
200 mg of the 4-aromatic amino acid decarboxylase inhibitor benserazide were administered orally to five patients with primary hypothyroidism. Benserazide induced a significant increase in prolactin and TSH plasma concentration in all subjects. Since the drug blocks the conversion of DOPA to dopamine, these hormonal changes may be due to a reduction in circulating and/or median eminence levels of dopamine.
D000328:Adult; D001545:Benserazide; D005260:Female; D006801:Humans; D006834:Hydrazines; D007037:Hypothyroidism / Q000097:blood / Q000503:physiopathology*; D008297:Male; D008875:Middle Aged; D011388:Prolactin / Q000097:blood / Q000378:metabolism*; D012636:Secretory Rate / Q000187:drug effects; D013268:Stimulation, Chemical; D013972:Thyrotropin / Q000097:blood / Q000378:metabolism*
D006834:Hydrazines; D001545:Benserazide; D011388:Prolactin; D013972:Thyrotropin